Trial · NCT05607316
Evaluating the Efficacy and Safety of Metformin in Vitiligo
NCT05607316, Phase 2, Withdrawn, University of Massachusetts, Worcester
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Efficacy and Safety of Metformin in Vitiligo. Trials, record NCT05607316. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05607316
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Efficacy and Safety of Metformin in Vitiligo
- NCT number
- NCT05607316
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Massachusetts, Worcester
- Conditions
- Vitiligo
- Interventions
- Metformin Hydrochloride
- First posted
- 2022-11-07
- Last updated
- 2024-09-24
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Define the different populations of cells by flow cytometry | Week 24 | Determine any change in the subpopulations of CD8+ T cells using CD69 and CD103 for Trm and CD122 (IL15Rb chain) as a marker for long-lived Trm; CD44, CD62L, and CD127 for central and effector memory T cells; and CXCR3 to indicate trafficking of CD8+ T cells. |
| Secondary | Define the inflammatory conditions in the lesions | Week 24 | Protein biomarker discovery using Olink® proteomics technology platform (inflammation panel) |
| Secondary | Measure the abundance of metabolites with untargeted metabolomics in the blister fluid and cells from non-lesional and lesional areas, and in plasma | Week 24 | Liquid chromatography-mass spectrometry |
| Secondary | Vitiligo Area Scoring Index 50% improvement (VASI50) after 6 months of treatment | Week 24 | Assess VASI at baseline and after 3 months of starting treatment. |
| Secondary | Face-Vitiligo Area Scoring Index 50% improvement (F-VASI50) after 6 months of treatment | Week 24 | Assess facial VASI at baseline and after 6 months of starting treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05607316
GET https://conductscience.org/api/trials/v1/NCT05607316/registered